Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Allergy Diagnostics and Therapeutics Market 

5.1. COVID-19 Landscape: Allergy Diagnostics and Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Allergy Diagnostics and Therapeutics Market, By Product

8.1. Allergy Diagnostics and Therapeutics Market, by Product, 2023-2032

8.1.1. Instruments

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Consumables

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Services

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Allergy Diagnostics and Therapeutics Market, By Drug Class

9.1. Allergy Diagnostics and Therapeutics Market, by Drug Class, 2023-2032

9.1.1. Nasal Anti-cholinergic

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Antihistamines

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Corticosteroids

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Mast Cell Stabilizers

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Leukotriene Inhibitors

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Epinephrine

9.1.6.1. Market Revenue and Forecast (2020-2032)

9.1.7. Immunotherapy

9.1.7.1. Market Revenue and Forecast (2020-2032)

9.1.8. Decongestants

9.1.8.1. Market Revenue and Forecast (2020-2032)

9.1.9. Immuno-modulators

9.1.9.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Allergy Diagnostics and Therapeutics Market, By Test

10.1. Allergy Diagnostics and Therapeutics Market, by March, 2023-2032

10.1.1. In vivo Test

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. In vitro Test

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Allergy Diagnostics and Therapeutics Market, By By Allergen Type

11.1. Allergy Diagnostics and Therapeutics Market, by By Allergen Type, 2023-2032

11.1.1. Food

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Inhaled

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Drug

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Other Allergens

11.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Allergy Diagnostics and Therapeutics Market, By End-user

12.1. Allergy Diagnostics and Therapeutics Market, by End-user, 2023-2032

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Diagnostics Labs

12.1.2.1. Market Revenue and Forecast (2020-2032)

12.1.3. Research & Development Centers

12.1.3.1. Market Revenue and Forecast (2020-2032)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Allergy Diagnostics and Therapeutics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.1.3. Market Revenue and Forecast, by Test(2020-2032)

13.1.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.1.5. Market Revenue and Forecast, by End-user (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.1.6.3. Market Revenue and Forecast, by Test(2020-2032)

13.1.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.1.6.5. Market Revenue and Forecast, by End-user (2020-2032) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.7.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.1.7.3. Market Revenue and Forecast, by Test(2020-2032)

13.1.7.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.1.7.5. Market Revenue and Forecast, by End-user (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.3. Market Revenue and Forecast, by Test(2020-2032)

13.2.4. Market Revenue and Forecast, by By Allergen Type (2020-2032) 

13.2.5. Market Revenue and Forecast, by End-user (2020-2032) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.6.3. Market Revenue and Forecast, by Test(2020-2032)

13.2.7. Market Revenue and Forecast, by By Allergen Type (2020-2032) 

13.2.8. Market Revenue and Forecast, by End-user (2020-2032) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.9.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.9.3. Market Revenue and Forecast, by Test(2020-2032)

13.2.10. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.2.11. Market Revenue and Forecast, by End-user (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.12.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.12.3. Market Revenue and Forecast, by Test(2020-2032)

13.2.12.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.2.13. Market Revenue and Forecast, by End-user (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.14.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.14.3. Market Revenue and Forecast, by Test(2020-2032)

13.2.14.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.2.15. Market Revenue and Forecast, by End-user (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.3. Market Revenue and Forecast, by Test(2020-2032)

13.3.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.3.5. Market Revenue and Forecast, by End-user (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.6.3. Market Revenue and Forecast, by Test(2020-2032)

13.3.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.3.7. Market Revenue and Forecast, by End-user (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.8.3. Market Revenue and Forecast, by Test(2020-2032)

13.3.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.3.9. Market Revenue and Forecast, by End-user (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.10.3. Market Revenue and Forecast, by Test(2020-2032)

13.3.10.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.3.10.5. Market Revenue and Forecast, by End-user (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.11.3. Market Revenue and Forecast, by Test(2020-2032)

13.3.11.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.3.11.5. Market Revenue and Forecast, by End-user (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.3. Market Revenue and Forecast, by Test(2020-2032)

13.4.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.4.5. Market Revenue and Forecast, by End-user (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.6.3. Market Revenue and Forecast, by Test(2020-2032)

13.4.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.4.7. Market Revenue and Forecast, by End-user (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.8.3. Market Revenue and Forecast, by Test(2020-2032)

13.4.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.4.9. Market Revenue and Forecast, by End-user (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.10.3. Market Revenue and Forecast, by Test(2020-2032)

13.4.10.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.4.10.5. Market Revenue and Forecast, by End-user (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.11.3. Market Revenue and Forecast, by Test(2020-2032)

13.4.11.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.4.11.5. Market Revenue and Forecast, by End-user (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.3. Market Revenue and Forecast, by Test(2020-2032)

13.5.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.5.5. Market Revenue and Forecast, by End-user (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.6.3. Market Revenue and Forecast, by Test(2020-2032)

13.5.6.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.5.7. Market Revenue and Forecast, by End-user (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.8.3. Market Revenue and Forecast, by Test(2020-2032)

13.5.8.4. Market Revenue and Forecast, by By Allergen Type (2020-2032)

13.5.8.5. Market Revenue and Forecast, by End-user (2020-2032)

Chapter 14. Company Profiles

14.1. R-Biopharm AG

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. EUROIMMUN Medizinische Labordiagnostika AG

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. DASIT Group SPA

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. bioMérieux

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Thermo Fisher Scientific, Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Stallergenes Greer

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Sun Pharmaceutical Industries Ltd

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Minaris Medical America, Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Siemens Healthcare GmbH

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. AESKU.GROUP GmbH

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms